THE PLACENTAL-TRANSFER OF MIFEPRISTONE (RU-486) DURING THE 2ND TRIMESTER AND ITS INFLUENCE UPON MATERNAL AND FETAL STEROID CONCENTRATIONS
THE PLACENTAL-TRANSFER OF MIFEPRISTONE (RU-486) DURING THE 2ND TRIMESTER AND ITS INFLUENCE UPON MATERNAL AND FETAL STEROID CONCENTRATIONS
复制标题
DOI：
10.1111/j.1471-0528.1990.tb01827.x
复制
发表时间：
1990-05-01
期刊：
影响因子：
--
通讯作者：
MACKENZIE, IZ
中科院分区：
文献类型：
--
作者：
HILL, NCW;SELINGER, M;MACKENZIE, IZ
一项双盲、安慰剂对照研究评估了孕中期孕妇服用抗孕激素米非司酮对母体和胎儿内分泌的影响。每组有六名女性。口服600毫克米非司酮4小时后，在母体和胎儿周围以及羊水中都检测到该药物。服用米非司酮或安慰剂后，母体循环中的孕酮、皮质醇、雌二醇或醛固酮浓度没有显著变化。服用米非司酮的孕妇胎儿醛固酮平均水平为1699(SD217)pmol/L，显著高于对照组的999(SD84)pmol/L，而孕酮、雌二醇和皮质醇水平无明显变化。这些结果的意义与米非司酮用于引产的可能治疗用途有关。
A double-blind, placebo-controlled study has assessed the maternal and fetal endocrine effects of the maternal administration of the anti-progestin mifepristone in mid-pregnancy. There were six women in each group. Four hours after oral administration of 600 mg mifepristone, the drug was detected in both maternal and fetal circluations and in the amniotic fluid. No significant changes in progesterone, cortisol, oestradiol, or aldosterone concentrations were detected in the maternal circulation after treatment with mifepristone or placebo. In women treated with mifepristone, the mean fetal aldosterone level was 1699 (SD 217) pmol/l which was significantly higher than the mean level of 999 (SD 84) pmol/l in the control group but no significant changes occurred in the fetal progesterone, oestradiol or cortisol concentrations. The significance of these results is discussed in relation to the possible therapeutic uses of mifepristone for inducing labour.